2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135767R
    Bicyclopyrone (Standard) 352010-68-5
    Bicyclopyrone (Standard) is the analytical standard of Bicyclopyrone. This product is intended for research and analytical applications. Bicyclopyrone is an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (Hpd).
    Bicyclopyrone (Standard)
  • HY-135878R
    2',5'-Dideoxyadenosine (Standard) 6698-26-6 98%
    2',5'-Dideoxyadenosine (Standard) is the analytical standard of 2',5'-Dideoxyadenosine. This product is intended for research and analytical applications. 2',5'-Dideoxyadenosine is a potent and non-competitive adenylyl cyclase inhibitor via binding the P-site with an IC50 of 3 µM . 2',5'-Dideoxyadenosine is a nucleoside analog and exerts a potent antiadrenergic action in heart.
    2',5'-Dideoxyadenosine (Standard)
  • HY-135897R
    Urolithin C (Standard) 165393-06-6
    Urolithin C (Standard) is the analytical standard of Urolithin C. This product is intended for research and analytical applications. Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca2+ channel opener and enhances Ca2+ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation.
    Urolithin C (Standard)
  • HY-137298A
    LYS006 hydrochloride 2619563-79-8 98%
    LYS006 hydrochloride is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LYS006 hydrochloride can be used for the research of inflammatory and autoimmune disorders.
    LYS006 hydrochloride
  • HY-13749BR
    Sitagliptin phosphate monohydrate (Standard) 654671-77-9
    Sitagliptin (MK-0431) phosphate monohydrate (Standard) is the analytical standard of Sitagliptin phosphate monohydrate (HY-13749B). This product is intended for research and analytical applications. Sitagliptin phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin phosphate monohydrate (Standard)
  • HY-13749CR
    (S)-Sitagliptin phosphate (Standard) 823817-58-9
    (S)-Sitagliptin (phosphate) (Standard) is the analytical standard of (S)-Sitagliptin (phosphate). This product is intended for research and analytical applications. (S)-Sitagliptin phosphate is the less active S-enantiomer of Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
    (S)-Sitagliptin phosphate (Standard)
  • HY-13749S3
    Sitagliptin-d6 1133211-99-0 98%
    Sitagliptin-d6 (MK-0431-d6) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin-d6
  • HY-137613B
    Rp-TTPαS 83199-35-3 98%
    Rp-TTPαS is a monomeric raw material that can be used for nucleic acid synthesis.
    Rp-TTPαS
  • HY-137619B
    Rp-dCTPαS 80951-76-4 98%
    Rp-dCTPαS is a monomeric raw material that can be used for nucleic acid synthesis.
    Rp-dCTPαS
  • HY-137620B
    Rp-dATPαS 87358-15-4 98%
    Rp-dATPαS is a monomeric raw material that can be used for nucleic acid synthesis.
    Rp-dATPαS
  • HY-137626B
    Rp-ATPαS 58976-49-1 98%
    Rp-ATPαS is a monomeric raw material that can be used for nucleic acid synthesis.
    Rp-ATPαS
  • HY-137658A
    Purine riboside-5'-O-triphosphate sodium 35892-95-6 98%
    Purine riboside-5'-O-triphosphate sodium, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC50 values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate sodium inhibits calmodulin-dependent protein kinase II (CaMKII) with a Ki value of 590 µM.
    Purine riboside-5'-O-triphosphate sodium
  • HY-13777S1
    Zoledronic acid-d3 1134798-26-7 98%
    Zoledronic acid-d3 (Zoledronate-d3) is the deuterium labeled Zoledronic acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects.
    Zoledronic acid-d3
  • HY-138257A
    (R)-Indeloxazine benzenesulfonate 1623762-83-3 98%
    (R)-Indeloxazine benzenesulfonate (AS1069562) is an orally active 5-HT and NE reuptake inhibitor, with IC50 values of 0.35 μM and 3.3 μM, respectively. (R)-Indeloxazine benzenesulfonate (AS1069562) possesses curative-like analgesic effect. (R)-Indeloxazine benzenesulfonate (AS1069562) might improve nerve function impairment via the amelioration of neurotrophic support.
    (R)-Indeloxazine benzenesulfonate
  • HY-13867AR
    Bisindolylmaleimide I hydrochloride (Standard) 176504-36-2 98%
    Bisindolylmaleimide I (hydrochloride) (Standard) is the analytical standard of Bisindolylmaleimide I (hydrochloride). This product is intended for research and analytical applications. Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a GSK-3 inhibitor.
    Bisindolylmaleimide I hydrochloride (Standard)
  • HY-139040R
    2-(Tetradecylthio)acetic acid (Standard) 2921-20-2 98%
    2-(Tetradecylthio)acetic acid (Standard) is the analytical standard of 2-(Tetradecylthio)acetic acid. This product is intended for research and analytical applications. 2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation.
    2-(Tetradecylthio)acetic acid (Standard)
  • HY-139576C
    Larsucosterol ammonium 2655654-16-1
    Larsucosterol (DUR-928) ammonium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol ammonium as a potent endogenous regulator decreases lipogenesis. Larsucosterol ammonium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1.
    Larsucosterol ammonium
  • HY-14197AR
    Clorgyline hydrochloride (Standard) 17780-75-5 98%
    Clorgyline hydrochloride (Standard) is the analytical standard of Clorgyline hydrochloride. This product is intended for research and analytical applications. Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research, structurally related to Pargyline (HY-A0091A). Clorgyline hydrochloride has little effect on the amounts of conjugated dopamine (DA) present in superfusate of slices from rat striatum. Clorgyline hydrochloride contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Clorgyline hydrochloride (Standard)
  • HY-14268S2
    Febuxostat-d3 98%
    Febuxostat-d3 (TEI 6720-d3) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat-d3
  • HY-14268S3
    Febuxostat-d5 98%
    Febuxostat-d5 (TEI 6720-d5) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat-d5
Cat. No. Product Name / Synonyms Application Reactivity